MarketScreener Homepage > Equities > Nasdaq > Voyager Therapeutics, Inc. VYGR

Report

Real-time Estimate Cboe BZX - 01/28 11:29:02 am
7.755	USD		+0.32%

01/27

SHAREHOLDER ACTION NOTICE : The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

01/26

VYGR SHAREHOLDER ALERT : Bronstein, Gewirtz & Grossman, LLC Notifies Voyager Therapeutics, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm

01/26

SHAREHOLDER ACTION REMINDER : The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

01/22/2021	01/25/2021	01/26/2021	01/27/2021	01/28/2021	Date
9.04(c)	8.69(c)	8.41(c)	7.73(c)	7.89	Last
318 838	457 014	267 270	430 211	84 682	Volume
+4.51%	-3.87%	-3.22%	-8.09%	+2.07%	Change

More quotes

Financials (USD)

Sales 2020	181 M - -
Net income 2020	28,9 M - -
Net cash position 2020	198 M - -
P/E ratio 2020	10,1x
Yield 2020	-

Sales 2021	56,0 M - -
Net income 2021	-109 M - -
Net cash position 2021	171 M - -
P/E ratio 2021	-3,01x
Yield 2021	-

Capitalization	290 M 290 M -
EV / Sales 2020	0,51x
EV / Sales 2021	2,11x
Nbr of Employees	186
Free-Float	84,6%

More Financials

Company

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal...

Sector

Biotechnology & Medical Research

Calendar

03/17

Ergebnisveröffentlichung

More about the company

Notations Surperformance© of Voyager Therapeutics, Inc.

Trading Rating :

Investor Rating :

More Ratings

All news about VOYAGER THERAPEUTICS, INC.

01/27	SHAREHOLDER ACTION NOTICE : The Schall Law Firm Announces the Filing of a Class ..	PR
01/26	VYGR SHAREHOLDER ALERT : Bronstein, Gewirtz & Grossman, LLC Notifies Voyager The..	PR
01/26	SHAREHOLDER ACTION REMINDER : The Schall Law Firm Announces the Filing of a Clas..	BU
01/25	SHAREHOLDER ALERT : Robbins LLP Announces That Voyager Therapeutics, Inc. (VYGR)..	BU
01/25	SHAREHOLDER ACTION ALERT : The Schall Law Firm Announces the Filing of a Class A..	BU
01/25	VYGR EQUITY ALERT : Rosen Law Firm Announces Filing of Federal Securities Class ..	BU
01/23	VOYAGER THERAPEUTICS : Pomerantz Law Firm Announces the Filing of a Class Action..	PR
01/22	PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-	DJ
01/15	VOYAGER THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K..	AQ
01/12	VOYAGER THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 563..	AQ
01/11	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 56..	GL
2020	VOYAGER THERAPEUTICS : Cantor Fitzgerald Downgrades Voyager Therapeutics to Neut..	MT
2020	AFTER HOURS WATCH LIST SCORECARD : Ocn, sppi, vygr	MT
2020	VOYAGER THERAPEUTICS : Raymond James Downgrades Voyager Therapeutics to Market P..	MT
2020	MT NEWSWIRES AFTER HOURS WATCH LIST : Ocn, sppi, vygr	MT

More news

News in other languages on VOYAGER THERAPEUTICS, INC.

2019

BB Biotech mit höherem Verlust im zweiten Quartal

More news

Analyst Recommendations on VOYAGER THERAPEUTICS, INC.

2020	VOYAGER THERAPEUTICS : Cantor Fitzgerald Downgrades Voyager Therapeutics to Neut..	MT
2020	VOYAGER THERAPEUTICS : Raymond James Downgrades Voyager Therapeutics to Market P..	MT
2020	BTIG Adjusts Price Target on Voyager Therapeutics to $18 From $31, Reiterates..	MT

More recommendations

Provided by Scoopnest.com

Chart VOYAGER THERAPEUTICS, INC.

Duration : Period :

Voyager Therapeutics, Inc. Technical Analysis Chart | VYGR | US92915B1061 | MarketScreener

Full-screen chart

Technical analysis trends VOYAGER THERAPEUTICS, INC.

	Short Term	Mid-Term	Long Term
Trends	Neutral	Bearish	Neutral

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	OUTPERFORM
Number of Analysts	13
Average target price	14,55 $
Last Close Price	7,73 $
Spread / Highest target	159%
Spread / Average Target	88,2%
Spread / Lowest Target	29,4%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
G. Andre Turenne	President, Chief Executive Officer & Director
Michael John Higgins	Chairman
Allison Dorval	Chief Financial & Accounting Officer
Omar Khwaja	Chief Medical Officer, Head-Research & development
Mark Jay Levin	Independent Director

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

VOYAGER THERAPEUTICS, INC.	8.11%	290



MODERNA, INC.	49.07%	61 624
LONZA GROUP AG	3.66%	49 275
CELLTRION, INC.	-10.58%	40 532
IQVIA HOLDINGS INC.	-3.44%	33 169
SEAGEN INC.	-7.11%	29 430

More Results